To receive your instant CME/CE certificate,
you must first "Sign In" or "Sign Up" in the top right corner.
MAXIMUM CREDITS: 1.0 AMA PRA Category 1 Credit™ or 1.0 contact hour
CLICK HERE TO PROCEED TO PROGRAM
Release Date: April 1, 2020
Termination Date: April 1, 2021
Estimated Time to Complete This CME/CE Activity: 1.0 hour
Medium or Combination of Media Used: Written article
Method of Physical Participation: Journal article, web-based posttest, and evaluation
Hardware/Software Requirements: High-speed internet connection, any web browser
Statement of Need
This activity provides a review of the properties and aesthetic uses of currently available neuromodulators (botulinum neurotoxin type A products) through a review of the literature, real-world cases, and expert clinical perspectives. The desired results of this activity are for health care practitioners to improve their ability to provide neuromodulators appropriately to their patients for optimal patient outcomes.
Upon completion of this activity, participants will be better able to:
- Explain the conversion ratios needed for individual neuromodulators based on clinical practice
- Use appropriate reconstitution procedures for the different neuromodulators
- Explain how to switch between neuromodulators to achieve optimal clinical outcomes
- Employ appropriate strategies for the management of complications to improve patient satisfaction
- Illustrate the most appropriate injection strategies for a variety of patients treated with neuromodulators
- Describe the anatomy of the face and neck that is relevant to ensure safe and effective treatment outcomes
This educational activity is intended for health care practitioners, including physicians, physician assistants, nurses, and nurse practitioners, with an interest in facial aesthetics.
Amedco designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™ for physicians and 1.0 contact hour for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Amedco and MedEdicus LLC. Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
How to Obtain CME/CE Credit
Learners must pass a posttest and complete an evaluation form to receive a certificate of completion online. Upon passing, you will receive your certificate of completion immediately. You must score 70% or higher to receive credit for this activity and may take the test up to 2 times. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Steve G. Yoelin, MD (Chair)
Steve Yoelin, MD, Medical Associates
Newport Beach, California
Shino Bay Aguilera, DO, FAAD
Shino Bay Cosmetic Dermatology and Laser Institute
Fort Lauderdale, Florida
Joel L. Cohen, MD
Director, AboutSkin Dermatology and DermSurgery
Director, AboutSkin Research
Greenwood Village and Lone Tree, Colorado
Associate Clinical Professor
University of California, Irvine
Michael H. Gold, MD, FAAD
Gold Skin Care Center
Tennessee Clinical Research Center
Joely Kaufman, MD, FAAD
Skin Associates of South Florida
Associate Professor of Dermatology
University of Miami Miller School of Medicine
Coral Gables, Florida
Corey S. Maas, MD, FACS
The Maas Clinic Facial Plastic and Aesthetic Surgery
San Francisco and Lake Tahoe, California
Associate Clinical Professor
University of California, San Francisco
San Francisco, California
Disclosure on Conflicts of Interest: The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1, 6.2, and 6.5)
All individuals in a position to control the content of CME/CE are listed. If their name is not listed below, they disclosed that they had no relevant financial relationships.
|Shino Bay Aguilera||Allergan; Dermira, Inc; Galderma Laboratories, LP; Merz, Inc; and SkinCeuticals||Consultant|
|Joel L. Cohen||Allergan; Biofrontera, AG; Biopelle, Inc; Endo Pharmaceuticals Inc; Evolus, Inc; Galderma Laboratories, LP; Lutronic; Merz, Inc; Revance Therapeutics, Inc; Sciton, Inc; SENTÉ Inc; Sonoma Pharmaceuticals, Inc; and Swiss-American CDMO, LLC||Consultant|
|Galderma Laboratories, LP; and Sciton, Inc||Speaker|
|Athenex, Inc; Biofrontera AG; BioMimetix Pharmaceutical, Inc; Biopelle, Inc; Brickell Biotech, Inc; Croma-Pharma GmbH; Dyve Biosciences; Endo Pharmaceuticals Inc; Evolus, Inc; Ferndale Healthcare, Inc; Galderma Laboratories, LP; Lutronic; Merz, Inc; and Revance Therapeutics, Inc||Contracted Research|
|Michael H. Gold||Aclaris Therapeutics, Inc; Aerolase Corp; ALASTIN Skincare, Inc; Allergan; Alma Lasers; Almirall, SA; Aquavitpharma; Bayer Corporation; Biofrontera AG; Brickell Biotech, Inc; Candela Corporation; Celgene Corporation; Clarisonic; Croma-Pharma GmbH; Cutanea Life Sciences, Inc; Dermata Therapeutics, LLC; Dermira, Inc; DUSA Pharmaceuticals, Inc; EndyMed Medical; Erchonia Corporation; Essence Novel; Exeltis; Galderma Laboratories, LP; Invasix; Johnson & Johnson Services, Inc; Joylux, Inc; Kadmon Holdings, Inc; L’Oréal; Lumenis; Merz, Inc; MTF Biologics; Novartis Pharmaceuticals Corporation; Pierre Fabre; Progenitor Biologics, LLC; Prollenium Medical Technologies; Promius Pharma, LLC; Revision Skincare; Sensus Healthcare; SENTÉ Inc; Sinclair Pharma; SkinCeuticals; Sonoma Pharmaceuticals, Inc; Stratpharma AG; Sun Pharmaceutical Industries Ltd; Suneva Medical, Inc; ThermiGen, LLC; Valeant; Viviscal Limited; XBiotech; and Zimmer Aesthetics||Consultant|
|Aclaris Therapeutics, Inc; Aerolase Corp; Almirall, SA; Clarisonic; Croma-Pharma GmbH; Cutanea Life Sciences, Inc; Erchonia Corporation; Essence Novel; Evolus, Inc; Galderma Laboratories, LP; Johnson & Johnson Services, Inc; Laboratoire Bioderma; L’Oréal; Prollenium Medical Technologies; Sensus Healthcare; SENTÉ Inc; Sinclair Pharma; SkinCeuticals; Sonoma Pharmaceuticals, Inc; Stratpharma AG; and ThermiGen, LLC||Advisory Board|
|Aclaris Therapeutics, Inc; ALASTIN Skincare, Inc; Biofrontera AG; Brickell Biotech, Inc; Croma-Pharma GmbH; Cutanea Life Sciences, Inc; Dermata Therapeutics, LLC; Dermira, Inc; Invasix; Kadmon Holdings, Inc; Merz, Inc; MTF Biologics; Prollenium; Revision Skincare; Valeant; and XBiotech||Contracted Research|
|Joely Kaufman||Allergan; Croma-Pharma GmbH; Cutera; Endo Pharmaceuticals Inc; Evolus, Inc; Galderma Laboratories, LP; Merz, Inc; and Revance Therapeutics, Inc||Contracted Research|
|Allergan; and Galderma Laboratories, LP||Speaker|
|Corey S. Maas||Allergan; Galderma Laboratories, LP; and Merz, Inc||Consultant|
|Allergan; Galderma Laboratories, LP; Merz, Inc; and Valeant||Speaker|
|Allergan; Evolus, Inc; Galderma Laboratories, LP; and Merz, Inc||Advisory Board|
|Allergan; Endo Pharmaceuticals Inc; Galderma Laboratories, LP; Merz, Inc; and Syneron Medical Ltd||Contracted Research|
|Steve G. Yoelin||Allergan; and Evolus, Inc||Consultant|
|Allergan; Merz, Inc; and Revance Therapeutics, Inc||Contracted Research|
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Amedco; MedEdicus LLC; Galderma Laboratories, LP; or the Journal of Drugs in Dermatology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure of Commercial Support: This continuing medical education activity is supported through an unrestricted educational grant from Galderma Laboratories, LP.
This CME/CE activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 179D
This continuing medical education activity is jointly provided by Amedco and MedEdicus LLC.
This continuing medical education activity is supported through an unrestricted educational grant from Galderma Laboratories, LP.
PROCEED TO PROGRAM